Johnson & Johnson

News

Anthos hails win over Xarelto with novel anticoagulant

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complic

News

J&J pulls out of Idorsia deal for hypertension drug

Idorsia has lost Johnson & Johnson's Janssen Biotech unit as the partner for its aprocitentan candidate for resistant hypertension, following a likely delay in the FDA

News

AI specialist Intelligent Omics bags J&J deal

UK artificial intelligence (AI) specialist Intelligent Omics has entered into a research collaboration with Johnson & Johnson, within weeks of joining the big pharma's

News

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least

News

FDA clears J&J's 2-in-1 tablet for prostate cancer

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

Anthos hails win over Xarelto with novel anticoagulant

J&J pulls out of Idorsia deal for hypertension drug

AI specialist Intelligent Omics bags J&J deal

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

FDA clears J&J's 2-in-1 tablet for prostate cancer

J&J bags first FDA approval for a GPRC5D drug

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks